Antisense Oligonucleotide Therapy to Correct CFTR Function in People with Cystic Fibrosis

Research output: ThesisDoctoral Thesis

129 Downloads (Pure)

Abstract

Cystic fibrosis (CF) is the most common life-threatening recessively inherited disease in Caucasians that has no cure. Novel therapeutics such as antisense oligonucleotides (AOs) have potential to be personalised treatments for people with CF. This thesis investigated 8 CFTR exons whose splicing could be altered with AOs. It was proposed that exon skipping to restore the CFTR reading frame could improve CFTR protein production for selected disease-causing mutations and reduce disease severity. Assessments were conducted in human primary airway epithelial cells, with lead AO sequences identified. Future work will investigate the functional capacity of the internally truncated CFTR protein.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
Supervisors/Advisors
  • Stick, Stephen, Supervisor
  • Laing, Ingrid, Supervisor
  • Kicic, Anthony, Supervisor
  • Fletcher, Susan, Supervisor
  • Wilton, Steve, Supervisor
Thesis sponsors
Award date5 Jul 2021
DOIs
Publication statusUnpublished - 2021

Fingerprint

Dive into the research topics of 'Antisense Oligonucleotide Therapy to Correct CFTR Function in People with Cystic Fibrosis'. Together they form a unique fingerprint.

Cite this